Harvey et al. [12] showed that SFN treatment restored bacteria recognition and phagocytosis in alveolar macrophages (AMs) from patients with COPD through activating nuclear factor erythroid 2 related factor 2 (Nrf2), to prevent exacerbation of COPD caused by bacterial infection. The gene discussed is NFE2L2; the disease is bacterial infectious disease.